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LipoproteinHepatitis C virus (HCV) infection is a major worldwide health problem. Our previous results showed that
HCV evolved to gain the enhanced infectivity and altered buoyant density distribution during persistent
infections in vitro. Here we showed that a point mutation I414T in HCV E2 was mainly responsible for these
phenotypic changes. While the I414T mutation had no signiﬁcant effect on HCV RNA replication and viral
entry, it enhanced the production of infectious viral particles and decreased the dependency of viral entry on
the levels of HCV receptors. Furthermore, we showed that the I414T mutation reduced the association of
viral particles with low-density lipoprotein or very low-density lipoproteins during the virus secretion
process, and the infection of the delipidated virus was more sensitive to the blockade by an anti-E2
neutralizing antibody and recombinant CD81 proteins. Our results provided more insights into under-
standing the roles of lipoprotein associations in HCV life cycle.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV), the causative agent of acute and chronic
hepatitis C, is a positive-strand RNA virus that belongs to the Flavi-
viridae family. More than 170 million people have been infected with
HCV worldwide, and many of them are subject to high risk of
developing liver cirrhosis and hepatocellular carcinoma (Lauer and
Walker, 2001). The HCV genome encodes a single polyprotein that is
processed by a combination of host and viral peptidases into at least
10 structural and nonstructural proteins. The structure proteins
include core, E1 and E2 that form virus particles. The non-structure
proteins include P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B
(Bartenschlager and Lohmann, 2000). The HCV envelope is formed
by the two heavily N-glycosylated type I transmembrane proteins E1
and E2, which are present on the surface of viral particles as
heterodimers anchored to a double-layer lipid membrane (Op De
Beeck et al., 2001).
Several putative HCV receptors/factors have been identiﬁed so far.
The tetraspanin molecule CD81 and the scavenger receptor class B
type I (SR-BI) were both identiﬁed as HCV receptors based on their
interactions with recombinant soluble E2 protein (Pileri et al., 1998;
Scarselli et al., 2002), and further conﬁrmed in the studies of infection
of HCV pseudotyped retroviral particles (HCVpp) (Bartosch et al.,
2003; Grove et al., 2007; Kapadia et al., 2007) and the recentlyll rights reserved.established in vitro infectious HCV system (HCVcc) (Kapadia et al.,
2007; Koutsoudakis et al., 2006, 2007; Tscherne et al., 2006; Voisset
et al., 2005). In addition, recent data support a role for claudin-1
(CLDN1) and occludin, components of the tight junctions, in a late
stage of HCV entry, presumably after the initial virus attachment and
binding to CD81 and SR-B1 (Evans et al., 2007; Liu et al., 2009; Ploss
et al., 2009). Other identiﬁed entry factors, including the low-density
lipoprotein (LDL) receptor (LDLR) (Agnello et al., 1999), glycosami-
noglycan (Barth et al., 2003), and asialoglycoprotein receptor (Saunier
et al., 2003), seem to act as nonspeciﬁc attachment factors to mainly
allow viral particles to concentrate on the cell surface.
HCV particles found in vivo and in vitro are heterogeneous in
density and size. HCV has long been known to associate with LDL and
very low-density lipoprotein (VLDL) circulating in patient blood
(Thomssen et al., 1992). HCV E1/E2 envelope proteins have been
found to bind to LDL, VLDL and high-density lipoprotein (HDL)
(Monazahian et al., 2000). Accumulating evidence suggests the
association between HCV and LDL/VLDL is important for virus entry
and virus egress (Chang et al., 2007; Gastaminza et al., 2008; Huang
et al., 2007; Meunier et al., 2008; Molina et al., 2007; Nahmias et al.,
2008), and HCVcc entry can be blocked by antibodies against
apolipoprotein C1 (Dreux et al., 2007; Meunier et al., 2005, 2008) or
apolipoprotein E (Chang et al., 2007).
Our previous studies showed that HCV infection could be
persistent in cell culture for up to 6 months during which the
virus evolved to gain the enhanced infectivity and altered buoyant
density distribution (Zhong et al., 2006). Here we reported that a
point mutation I414T in E2 was responsible for the changes of viral
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mutation had no signiﬁcant effect on HCV RNA replication and
viral entry, it promoted the production of infectious viral particles
and reduced the dependency of viral entry on the levels of HCV
receptors. Furthermore, we showed that the I414T mutation reduced
the association of viral particles with LDL/VLDL during the virus
secretion process, and the infection of this less lipidated virus was
more sensitive to the blockade by an anti-E2 neutralizing antibody
and recombinant CD81 proteins, but less sensitive to anti-apolipo-
protein antibodies. Our results provided more insights into the
understanding of the roles of lipoprotein associations in HCV life
cycle.
Results
I414T accelerated JFH-1 infection kinetics and increased viral titers
In our previous studies, we established persistent HCV infection in
cell culture for up to 6 months. During the persistent infection, the
viral infectivity was greatly enhanced (Zhong et al., 2006). Our
sequencing analysis revealed that three point mutations in E2, V388P,
I414T and L644I, were selected during a persistent HCV infection (Exp
2 in (Zhong et al., 2006)). To examine the effect of this mutation on
HCV infection, we engineered each individual mutation to JFH-1 and
obtained recombinant mutant viruses as described in Materials and
methods. Next we compared the ability of the wild-type and mutant
viruses in expanding in naïve cells. Naïve Huh-7.5.1 cells were
inoculated with V388P, I414T, L644I or wild-type viruses at a
multiplicity of infection (MOI) of 0.005, and the supernatant
infectivity titers at the indicated time points after the inoculationFig. 1. The I414T mutation enhanced JFH-1 infectivity. Huh-7.5.1 cells were infected with wil
collected at the indicated days and analyzed for the infectivity titers by a titration assay. (B) I
cellular GAPDH levels. The error bar represented triplicates of each time point. (C) Immunowere determined by the titration assay. As shown in Fig. 1A, V388P
and L644I did not accelerate HCV expansion kinetics, while the I414T
mutant virus expanded faster than wild-type JFH-1, and the peak
titers of I414Twere about 5-fold higher than that of wild type.We also
determined the intracellular HCV RNA levels at the indicated time
points after the inoculation of wild-type and I414T viruses by
quantitative RT-PCR. Consistently, I414T virus expanded faster than
the wild-type JFH-1 (Fig. 1B). Furthermore, immunoﬂuorescence
staining of HCV E2 proteins in the infected cells at day 5 post-infection
showed that I414T virus expanded to about 70% of total cell
population while wild type expanded to only 20% (Fig. 1C). These
results demonstrated that the I414T mutation enhanced JFH-1
infectivity.
I414T did not enhance viral entry
HCV glycoprotein E2 interacts with cellular receptors CD81 and
SR-B1 that mediate HCV entry (Op De Beeck et al., 2001). It is possible
that the I414T mutation in E2 could improve JFH-1 infectivity by
enhancing HCV entry. To test this hypothesis, we ﬁrst analyzed the
entry of wild-type and I414T JFH-1 infection in Huh-7.5.1 cell. The
same infectious units of wild-type and I414T viruses were incubated
with Huh-7.5.1 cells. At the indicated time points, the viral inocula
were removed and the cells were supplemented with fresh complete
medium. The number of viruses that had entered the cells and the
number of remaining viruses in the viral inocula at each time point
after inoculation were determined, respectively. As shown in Figs. 2A
and B, no signiﬁcant difference was observed between wild type and
I414T, suggesting that the I414Tmutation did not confer an advantage
at the level of HCV entry. To further conﬁrm this, we compared thed-type or E2mutant JFH-1 viruses at an MOI of 0.005. (A) Cell culture supernatants were
ntracellular HCV RNA levels were determined by quantitative RT-PCR and normalized to
ﬂuorescence staining of HCV E2 proteins in the infected cells at day 5 post-infection.
Fig. 2. I414T did not enhance JFH-1 entry. (A and B) Infection of wild-type and I414T
viruses in Huh-7.5.1 cells. Fifty infectious units of wild-type and I414T JFH-1 were
inoculated to Huh-7.5.1 cells and withdrawn at the indicated time points. (A) The
number of viruses that had entered the cells was quantiﬁed by immunoﬂuorescence
staining at 72 h post-infection. The data were expressed as the percentage of HCV-
positive focus number to that at 9 h post-infection (30 ffu). The error bar represented 12
replicates. (B) The number of remaining viruses in the withdrawn viral inocula was
determined by a titration assay. The data were expressed as the percentage of total
input (50 ffu). The error bar represented four replicates. (C) The infection of Huh-7.5.1
cells with HCVpp bearing the wild-type or I414T mutant E2 proteins. HCVpp produced
from transfection of HEK293T cells were normalized according to their HIV p24
contents, and then were used to infect Huh-7.5.1 cells for 3 days. The lysate of infected
cells were assayed for the luciferase activities. The error bar represented triplicates.
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type or I414Tmutant E2 proteins (Fig. 2C). No differencewas detected
between wild type and I414T either.
Next we analyzed the binding of soluble E2 protein (sE2)
containing the I414T mutation to the HCV receptors CD81 or SRB1.
The recombinant his-tagged sE2 proteins were prepared as de-
scribed in Materials and methods, and quantiﬁed by western blot
using an anti-his antibody. The normalized wild-type and I414T
mutant sE2 proteins were incubated with CHO cells stably expres-sing human CD81 or SRB1, and the binding of sE2 to CHO-CD81 or
CHO-SRB1 cells was detected by FACS. As shown in Fig. 3, the I414T
mutation did not appear to enhance sE2 interaction with human
CD81 or SRB1. Altogether, these data suggest that the I414T muta-
tion did not facilitate HCV entry.
I414T enhanced production of infectious viral particles
To determine whether I414T has any effects on virus production,
we engineered the I414T mutation to the JFH-1 full-length genomic
replicon that is bi-cistronic and harbors a neomycin-resistant marker
(Fig. 4A). It has been shown that the cells stably replicating the JFH-1
full-length genomic replicon RNA were able to produce infectious
viruses (Akazawa et al., 2008), therefore to eliminate the effect of re-
infection on the quantiﬁcation of virus production, we transfected the
JFH-1 full-length genomic replicon RNA into R3 cell line, a CD81-
negative Huh-7 cell that does not support JFH-1 infection (Zhong et al.,
2006). After the G418 selection, the survival colonies were pooled,
expanded and analyzed for HCV RNA levels in the cells and infectivity
titers in the culture supernatants. As shown in Fig. 4B, the intracellular
HCV RNA levels of the I414T replicon cells were comparable with that
of wild type, but the infectivity titers in the supernatants of the I414T
replicon cells were about 4 times higher than that of wild type
(Fig. 4B). To further distinguish whether the increase of infectivity
titers was due to the increase of general virus production or the
increase of proportion of infectious viral particles among the total
supernatant encapsidated HCV RNA, wemeasured the HCV RNA levels
in the culture supernatants. As shown in Fig. 4B, the total HCV RNA
levels in the I414T replicon cell supernatants were similar to those in
the wild-type replicon cell supernatants, suggesting that I414T only
increased the proportion of infectious particles among the total viral
particles in the supernatants.
The enhanced virus production could result from the improved
viral assembly or from the improved virus secretion. To investigate at
which stage I414T improved virus production, we compared
intracellular and extracellular HCV infectivity titers of the wild-type
and mutant viruses. The intracellular viruses were prepared as
previously described (Gastaminza et al., 2008). As shown in Fig. 4C,
while the levels of intracellular viral infectivity were comparable, the
I414T extracellular infectivity was about four-fold higher than wild
type. The ratio of extracellular and intracellular viral infectivity was
188:1 for I414T and 56:1 for wild type. These data suggest I414T
enhanced virus production by improving virus secretion.
I414T changed the buoyant density of JFH-1 virus
To compare biophysical properties of the viral particles, we
analyzed the buoyant densities of wild-type and I414T viruses
collected from culture supernatants in a 20–60% sucrose gradient
ultracentrifugation. As expected, the infectivity of both wild-type and
I414T viruses was distributed over a broad range of buoyant density.
However, the infectivity in the lowest-density fraction of I414T was
signiﬁcantly reduced compared with that of wild type (Fig. 5A).
Analysis of HCV RNA content of each fraction showed that the
mutation caused the similar density change (Fig. 5B). It has been
shown by a number of laboratories that matured HCV particles are
associated with LDL or VLDL, rendering the heterogeneous buoyant
density of viral particles, and LDL/VLDL is added to intracellular
infectious HCV particles as the viruses exit host cells (Gastaminza
et al., 2008). The lack of infectivity at the lowest density fraction may
be indicative of less LDL/VLDL association in I414T viral particles
during virus secretion. To test this hypothesis, we analyzed the
buoyant density of intracellular wild-type and I414T mutant viral
particles. As shown in Fig. 5C, both intracellular viral particles had a
peak infectivity titer at the density of around 1.15 g/l, with no
signiﬁcant difference between wild type and I414T. These data
Fig. 3. I414T did not enhance the binding of E2 to human CD81 or SRB1. The his-tagged wide-type or I414T soluble E2 proteins were incubated with CHO cells stably expressing (A)
human SRB1 or (B) human CD81 on the cell surface. Naïve CHO cells were used asmock control. The binding efﬁciency was detected by FACS analysis using amousemonoclonal anti-
his tag antibody, followed by a goat-anti-mouse secondary antibody labeled with Alexa555. The number in the panel shows the percentage of sE2 binding cells.
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thewild-type and I414Tmutant extracellular viral particles may occur
during the process of viral particle secretion, likely due to the different
VLDL/LDL association.The entry of I414T was less dependent upon the levels of host cell receptors
I414T mutation was selected from a persistent HCV infection
during which host cells evolved to become less permissive for JFH-1
Fig. 4. The I414Tmutation enhanced the production of infectious viral particles. (A) The
structure of JFH-1 full-length genomic replicon. (B) The intracellular and supernatant
HCV RNA levels and supernatant viral infectivity of R3 cells (CD81-negative subclone of
Huh7) that stably expressed the wild-type or I414T JFH-1 full-length genomic replicon
RNA. HCV RNA levels were analyzed by quantitative RT-PCR and normalized to the
internal GAPDH control. The error bar represented two replicates. The supernatant
infectivity titers were determined by a titration assay and normalized to the number of
cells from which the viral supernatants were collected. HCV RNA levels were analyzed
by quantitative RT-PCR. The error bar represented three replicates. All data were
expressed as the percentage of wild type. The wild-type intracellular HCV RNA levels,
supernatant infectivity and supernatant HCV RNA levels were 2.6×107 copies/g total
RNA, 180 ffu/ml and 5.8×105 copies/ml respectively. (C) The intracellular and
supernatant HCV infectivity of Huh-7 cells that were persistently infected by wild-type
or I414T mutant viruses. Intracellular and supernatant viruses were prepared as
described in Materials and methods. Infectivity was detected by titration assay.
Fig. 5. I414T changed the buoyant density of JFH 1 virus. The extracellular (A and B) and
intracellular (C) viral particles of wild-type and I414T JFH-1 were analyzed in a 20-60%
sucrose gradient. The infectivity titers (A and C) and HCV RNA levels (B) of each fraction
were determined by titration assay and quantitative RT-PCR respectively. The data were
expressed as the percentage of the total titers of all density fractions.
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2006). It was conceivable to speculate that the I414T mutation may
confer an advantage at the step of viral entry when the CD81 levels on
the host cell surface are reduced. To test this hypothesis, we compared
the entry of wild-type and I414T JFH-1 viruses in the Huh-7.5.1 cells
that were treated with a serial dose of anti-CD81 monoclonal
antibodies. Interestingly, as shown in Fig. 6A, the infection of I414T
was less sensitive to the anti-CD81 antibody blockade than that of
wild type. Next we compared the entry of wild-type and I414T JFH-1
viruseswhen SR-B1 on the host cell surfacewas blocked by anti-SR-B1
sera. In consistent with the CD81 blockade, the blockade of SR-B1 on
the host cell surface inhibited wild type more efﬁciently than I414T
(Fig. 6B). Claudin-1 was recently identiﬁed as an important HCV entry
factor. Therefore, we also compared the infection of wild-type and
I414T JFH-1 viruses in the Huh-7.5.1 cells in which the claudin-1expression levels were reduced by a claudin-1 speciﬁc shRNA. The
western blot analysis showed that the claudin-1 speciﬁc shRNA
decreased the expression of claudin-1 in a dose-dependent manner
(data not shown). Importantly, as shown in Fig. 6C, the infection of
I414T was less sensitive to the reduction of claudin-1 levels than that
of wild type. Altogether, these data indicated that the infection of
I414T virus was less dependent upon the levels of viral receptors/co-
receptors on the host cell surface.
I414T was more sensitive to an anti-E2 neutralizing antibody and
CD81-LEL treatment
Our foregoing results suggested the I414T mutation in E2 reduced
the association of viral particleswith LDL/VLDL,whichmay lead tomore
exposure of viral envelope glycoproteins on viral particles. To test this
hypothesis, we ﬁrst determined the sensitivity of wild type or I414T
infection to a previously reported human anti-E2 monoclonal antibody
(Lawet al., 2008).As shown in the Fig. 7A, the anti-E2 antibody inhibited
Fig. 6. The I414T virus infection was less dependent on the availability of host receptors.
Huh-7.5.1 cells were pre-incubated with (A) anti-CD81 monoclonal antibody (clone
5A6) or (B) Rat anti-SR-B1 serum at the indicated doses at 37 °C for 1 h, and then
infected with the same infectious units of wild-type or I414T JFH-1. The infection was
analyzed with immunoﬂuorescence staining, and the data were expressed as the
percentage of infection in the mock treated Huh-7.5.1 cells. (C) Huh-7.5.1 cells were
transduced with lentiviruses expressing claudin-1 speciﬁc shRNA, followed by the
infection with wild-type or I414T mutant JFH-1. The intracellular HCV RNA levels were
determined by quantitative RT-PCR. The data were expressed as the percentage of
infection in the mock treated Huh-7.5.1 cells. The error bar represented three replicates
(⁎Pb0.05).
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Consistently, the infection of I414T was more sensitive to recombinant
large extracellular loop of CD81, a binding site of HCV E2 (Fig. 7B).
Interestingly, however, the anti-E2 monoclonal antibody blocked theinfection of wild-type and I414T mutant HCVpp at a similar efﬁciency
(Fig. 7C), presumably because HCVpp may lack lipoprotein association
during HCVpp genesis in HEK293T cells (Burlone and Budkowska,
2009).Altogether, thesedata indicated thatHCVenvelope glycoproteins
on the I414T viral particles were more accessible for the neutralizing
antibody or receptor binding.
The LDL/VLDL association determined the sensitivity of JFH-1 to the
anti-E2 neutralizing antibody
To further conﬁrm that I414T mutation increased the sensitivity of
JFH-1 to the anti-E2 neutralizing antibody by reducing the LDL-VLDL
association of viral particles, we used the anti-E2 antibody to
neutralize the infection of intracellular wild-type or I414T viruses
which share the similar buoyant density due to the lack of LDL/VLDL
association. As shown in Fig. 8A, although the anti-E2 antibody
inhibited the infection of extracellular I414T virus more efﬁciently
than that of extracellular wild-type virus, no signiﬁcant difference in
the blocking efﬁciency was observed between the intracellular wild
type and I414T. In addition, the intracellular viruses that lacked the
LDL/VLDL association was apparently more sensitive to the anti-E2
neutralizing antibody than the extracellular viruses, providing
additional evidence that the LDL/VLDL association reduces the
sensitivity of HCV to the anti-E2 neutralization.
It has been reported that HCV viral particles were associated with
apoE and apoC, and the antibodies against these apolipoproteins were
able to neutralize HCV infection (Chang et al., 2007; Meunier et al.,
2008). Therefore, we compared the sensitivity of wild type and I414T to
anti-apoE or anti-apoC antibodies. As shown in Figs. 8B and C, I414T
infection was less sensitive to the apolipoprotein blockade, suggesting
that the mutant virus may have less apolipoprotein contents. Further-
more, we compared the sensitivity of extracellular and intracellular
wild-type JFH-1 to the apolipoprotein blockade. As shown in Fig. 8D,
similar to the I414T extracellular viruses, the infection of the intra-
cellular wild-type viruses was less sensitive to the ApoE blockade.
Altogether, these data strongly suggested that the virus–lipoprotein
association could determine the interactions between the viral glyco-
proteins and their receptors or neutralizing antibodies.
Discussion
It has been reported by many groups that the infectivity of HCV
could be enhanced during a long-term cell culture. Many mutations
have been identiﬁed across the HCV genome that are responsible for
the enhancement of infectivity (Delgrange et al., 2007; Kaul et al.,
2007; Russell et al., 2008; Zhong et al., 2006). In our studies we found
that the mutation of isoleucine to threonine at amino acid 414 in E2
led to more rapid viral expansion kinetics, higher infectious titers,
increased speciﬁc infectivity and buoyant density changes. The HCV
RNA levels in the wild-type and I414T mutant full-length genomic
replicon cells or in the cell culture supernatants were similar, sug-
gesting this mutation did not enhance HCV RNA replication in the cells
or general virus particles secretion. Nevertheless, the I414T culture
supernatants possessed about 4 times more infectious viral particles
than wild type, indicating this mutation increased the proportion of
infectious viral particles among total encapsulated HCV RNA popula-
tion. Given the fact that HCV E2 glycoprotein is important for HCV
entry, this mutation could give virus an advantage at the stage of virus
entry. However, our results indicated that this mutation did not
accelerate HCVcc or HCVpp entry in Huh-7.5.1 cells. Instead, inter-
estingly, this mutation did confer an advantage at the virus entry
when the levels of host receptors (CD81, SR-B1 or Claudin-1) were
reduced. These results should make sense because the mutation was
selected from a persistent HCV infection cell culture during which
host cells became less permissive for HCV infection by reducing the
CD81 levels on the cell surface. The I414T mutation that reduced the
Fig. 7. I414T was more sensitive to an anti-E2 neutralizing antibody and CD81-LEL
treatment. Thewild-type or I414Tmutant viruses were pre-incubated with a serial dose
of (A) an anti-E2 neutralizing antibody or (B) CD81 LEL for 1 h at 37 °C, and then used to
infect Huh-7.5.1 cells. The infection was analyzed at 72 h post-infection by
immunoﬂuorescence staining. (C) The wild-type or I414T mutant HCVpp were
blockaded by the anti-E2 neutralizing antibody and HCVpp infection was determined
by luciferase reporter assay. The data were expressed as the percentage of infection in
the mock treated virus. The error bar represented three replicates (⁎⁎Pb0.01).
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beneﬁt viral survival during the persistent infection.
HCV is believed to closely associate with host derived LDL/VLDL
and exist in patient blood and in cell culture supernatants in a form of
lipoprotein–virus complex. The change of buoyant density of the
I414T mutant virus may be an indicative of an altered interaction ofviral particles with lipoproteins. We hypothesized that the lack of
infectivity in the lowest density fraction of the I414T mutant virus
resulted from the reduction of association with LDL/VLDL during the
virus secretion process. This hypothesis was supported by the
observation that the delipidated intracellular viral particles of I414T
shared a similar buoyant density distribution with that of wild type.
Furthermore, our results showed that the infection of I414T mutant
virus was much more sensitive to blockade by an anti-E2 neutralizing
antibody or the recombinant CD81-LEL than that of the wild-type
virus, while this difference was not observed in the infection of the
delipidated intracellular HCVcc or HCVpp. Our interpretation for this
observation was that the reduction of virus–lipoprotein association
leads to more exposure of envelope glycoproteins on the surface of
viral particles, making them more accessible for the neutralizing
antibody or cell receptors. We also found that the infection of I414T
virus was less sensitive to the blockade by the anti-ApoC1 or anti-
ApoE antibody, supporting the notion that there were less apolipo-
protein contents in the mutant viral particles. Recently Grove et al.
(2008) reported another point mutation G451R in E2 that arose
during the persistent infection in vitro. Although some differences
exist between these two mutant viruses, such as the CD81 binding
afﬁnity and the dependency of virus infection on HCV receptors, both
studies established a strong relationship between viral infectivity and
virus–lipoprotein association. An important remaining question is
how these mutations in E2 alter the lipoprotein association during the
virus secretion process. Obviously more investigation will be needed
to address this question.
Materials and methods
Cell culture, in vitro transcription, and HCV RNA transfection and
molecular cloning
The cell culture condition and protocols for in vitro transcription
and HCV RNA electroporation have been described previously (Zhong
et al., 2005). Individual viral mutations were introduced into the pJFH-
1 plasmid (Kato et al., 2003) by two-step recombinant PCR using
primers containing themutation, followed by restriction digestion and
ligation. To make the HCV E1-E2 expression constructs for HCVpp
genesis, the wild-type or I414T mutant E1 and E2 sequences were
ampliﬁed by PCR and inserted into the BamHI and NotI sites of
pCDNA3.1. To make CD81 and SRB1 expression constructs, human
CD81 and SRB1 cDNAs were ampliﬁed by PCR and inserted into the
HindIII andNotI sites of pLEGFP-N1. Tomake the soluble E2 expression
constructs, the C-terminal truncated wild-type or I414T mutant E2
sequences (384–687) were added a histidine tag at the C-terminal
by PCR using the primers -GGAGCAGTCTTCGTTTCGCCCGGCACCAC-
CACCGTTGGAGGC- and -CACAGCAGATCTTTAGTGGTGGTGGTGGT-
GGTGGGGTAAGTCTGAGTAGGTGCAGGG-(C-terminal histidine tag is
italicized). The tPA fragment was ampliﬁed using the sense primer -
CATGGGTCTTTTCTGCAGTCACCGTCCTTAGAT- and the antisense
primer -GCCTCCAACGGTGGTGGTGCCGGGCGAAACGAAGACTGCTCC-.
The E2 fragments were then fused with the tPA fragment by PCR,
and inserted into the BglII and PstI sites of pVIJns vector (Scarselli
et al., 2002). All constructs were veriﬁed by DNA sequencing.
RNA analysis, indirect immunoﬂuorescence, titration analysis, HCV
infection kinetics assay and sedimentation equilibrium gradient analysis
These analyses were performed as previously described (Zhong
et al., 2005).
Intracellular particle preparation
Twenty million Huh-7.5.1 cells infected with wild-type or I414T
mutant viruses were collected by trypsinization and resuspended in
Fig. 8. LDL-VLDL association altered the sensitivity of HCV infection to the E2 neutralization. (A) The wild-type or I414T extracellular or intracellular viruses were assayed for their
sensitivities to the neutralization by an anti-E2 monoclonal antibody. (B and C) The wild-type or I414T extracellular viruses were assayed for their sensitivities to an anti-ApoC1
antibody (B) or anti-ApoE antibody (C). (D) The extracellular or intracellular wild-type JFH-1 viruses were assayed for their sensitivities to the anti-ApoE antibody. In all cases, the
viruses were pre-incubated with the antibodies for 1 h at 37 °C, and then inoculated to Huh-7.5.1 cells for 4 h. The intracellular RNA levels at 72 h post-infection were analyzed by
quantitative RT-PCR. The data were expressed as the percentage of the mock treatment control. The error bar represented three replicates.
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cycles between−80 °C isopropanol and a 37 °Cwater bath. Cell debris
was removed by centrifugation twice at 4000 rpm for 5 min. The
supernatant was collected and used for the infection.
Virus entry assay
Fifty focus-forming units of wild-type or I414T viruses were
inoculated to 1×104 Huh-7.5.1 cells. The inocula were removed at the
indicated time points and transferred to 1×104 naïve Huh-7.5.1 cells
in a 96-well to quantify the number of viruses that have not entered
the cells. In the meantime, the inoculated cells were washed three
timeswith PBS and cultured in fresh completemedium. The cells were
ﬁxed at 72 h post-infection and analyzed by indirect immunoﬂuo-
rescence staining as previously described (Zhong et al., 2005).
JFH-1 replicon RNA transfection
Ten micrograms of in vitro-transcribed full-length JFH-1 replicon
RNA containing a neo marker (Date et al., 2007) was electroporated
into 4×106 R3 cells, CD81 negative subclone of Huh7 cells (Zhong
et al., 2006). After electroporation, one-third of the cells were plated
in a 10-cm dish. G418 (500 μg/ml) was added 1 day after transfection
and was refreshed every 3 to 4 days. G418-resistant colonies were
pooled to expand or stained with crystal violet 3 weeks after
transfection.
Blockade of HCV infection by an anti-CD81 antibody and anti-SR-B1 serum
Ten thousand of Huh-7.5.1 cells in a 96-well plate were pretreated
with 0, 0.1, 0.25, 1, 2.5, and 25 μg/ml of CD81 antibody (clone 5A6;
Santa Cruz Biotechnology, Santa Cruz, CA) or 1:25, 1:50, 1:100 dilutedanti SR-B1 rat serum (Zeisel et al., 2007) for 1 h and then infected with
50 focus-forming units of the wild-type or I414T mutant viruses for
5 h. The viruses were removed, and the cells were washed with PBS
and then supplemented with complete medium. The efﬁciency of the
infection was determined 3 days later by counting the number of
HCV-positive foci by immunoﬂuorescence as described above.
Blockade of HCV infection by CD81-LEL, anti-E2, anti-ApoC1 or
anti-ApoE antibodies
Fifty focus-forming units of the wild-type or I414T mutant viruses
were pre-incubated with various amount of puriﬁed large extracel-
lular loop (LEL) of CD81 (Drummer, Wilson, and Poumbourios, 2002),
anti-E2 (Law et al., 2008), anti-ApoC1 (Biodesign, Saco, ME) or anti-
ApoE (Merck, Whitehouse Station, NJ) antibodies at 37 °C for 1 h, and
then added to 1×104 Huh-7.5.1 cells for 8 h. The viruses were
removed, and the cells werewashedwith PBS for three times and then
supplemented with complete medium. The efﬁciency of the infection
was determined 3 days later by quantitative RT-PCR analysis or by
immunoﬂuorescence staining as described above.
HCVpp genesis and infection
HCV pseudotyped retroviral particles (HCVpp) were generated as
previously described (Hsu et al., 2003). Brieﬂy 293T cells were co-
transfected with the envelope-deﬁcient HIV genome pNL4-3.Luc.R-.E-
and a plasmid expressing wild-type or I414T mutant glycoproteins.
The medium was replaced with complete medium after 18 h.
Supernatants were collected after 72 h and clariﬁed by centrifugation.
For infection experiments, HCVpp supernatants were ﬁrst normalized
according to their HIV p24 levels by western blot, and then were used
to infect 1×104 Huh-7.5.1 cells for 72 h. The infected cells were lysed
75W. Tao et al. / Virology 395 (2009) 67–76with 20 μl of cell culture lysis reagent (Promega, Madison, WI), and
infection was measured by quantifying the expression of the
luciferase reporter using 50 μl of luciferase substrate (Promega) and
a Centro LB960 luminometer (Berthold Technologies, Bad Wildbad,
Germany). The neutralization of HCVpp infection was carried out by
pre-incubating 150 μl of wild-type or I414T mutant HCVpp with a
serial dilution of anti-E2 antibodies (Law et al., 2008) at 37 °C for 1 h,
and then added to 3×104 Huh-7.5.1 cells for 72 h. The efﬁciency of
the infection was determined by the luciferase assay as described
above.
Soluble E2 protein binding assay
HEK293T cells were transfected with 10 μg of plasmids expressing
His-tagged HCV E2 proteins by the calcium phosphate method.
Culture supernatants were harvested 72 h after transfection,
concentrated 60 times using centrifugal ﬁlter devices (Amicon®
Ultra-15, 10000 MWCO). The lentiviral vector pLEGFP-N1 (Invitro-
gen) containing human CD81 or SR-B1 was co-transfected with the
plasmids expressing HIV gal-pol protein and VSV glycoprotein into
HEK293T cells. The supernatants collected at 72 h post-transfection
were used to transduce CHO cells. The expression of the receptors on
the cell surface was conﬁrmed by FACS using a mouse anti-hCD81
monoclonal antibody (clone 5A6, Santa Cruz Biotechnology) or Rabbit
anti-hSRB1 antibody (NB400-104, Novus, Littleton, CO). The CD81-
positive cells were sorted out, and then expanded for the E2 binding
assay. To analyze the binding of sE2 to the receptors, 150 μl of
concentrated sE2 culture supernatants were incubated with parental
CHO cells or with CHO cells expressing SR-BI or CD81 at 37 °C for 1 h.
After washing with PBS, the cells were incubated with 800 ng of anti-
His mouse monoclonal antibody (Sigma, St. Louis, MO) on ice for
30 min, and thenwith 50 ng of Alexa555-conjugated goat-anti-mouse
IgG (Invitrogen), followed by FACS analysis on a FACS Calibur ﬂow
cytometer (BD Biosciences, San Diego, CA).
RNA interference
Vector pSQR expressing shRNAs targeting the CLDN1 reference
sequence (Sigma) was transfected into HEK293T cells together with
two packaging plasmids encoding VSV glycoprotein and GAG-pol
(Rubinson et al., 2003). The resulting supernatants were collected
72 h after transfection, clariﬁed by centrifugation and used to infect
Huh-7.5.1 cells. The expression levels of CLDN1 in infected cells were
determined by western blot using a mouse anti-CLDN1 monoclonal
(Zymed Laboratories, San Francisco, CA).
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